Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
The correlation of technetium-99m-HMDP bone scintigraphic findings, serum osteocalcin as a measure of bone turnover and prostate-specific antigen (PSA) and/or prostate acid phosphatase (PAP) was determined in 19 men with bone metastasis due to prostatic carcinoma. Six of the 19 patients with metastases on bone scan showed elevation of osteocalcin. These patients had extensive metastatic disease. All 19 men with positive bone scans had high serum PSA and/or PAP levels. Serum osteocalcin measurement is less sensitive to detection of bone deposits than PSA/PAP measurements (p less than 0.0008).
Nuclear Medicine Service, VA Medical Center, Lexington, Kentucky.
W J
WJ
Shih
B
B
Wierzbinski
J
J
Collins
S
S
Magoun
I W
IW
Chen
U Y
UY
Ryo
D000135:Acid Phosphatase / Q000097:blood*; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms; D011877:Radionuclide Imaging; D013669:Technetium Tc 99m Medronate
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015675:Osteocalcin; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen; D013669:Technetium Tc 99m Medronate